Omnitrope

Pediatric Growth Conditions

Omnitrope is used to treat children who have growth failure or are significantly shorter than their peers due to several specific medical conditions:

• Growth Hormone Deficiency: A condition where the pituitary gland does not produce enough natural growth hormone.
• Prader-Willi Syndrome: A genetic disorder that affects growth, muscle tone, and body composition.
• Turner Syndrome: A chromosomal condition in females that often results in short stature.
• Small for Gestational Age (SGA): For children born smaller than expected who do not reach a normal height range by age two.
• Idiopathic Short Stature: For children who are very short for their age without a known medical cause.

Adult Growth Hormone Deficiency

In adults, Omnitrope is prescribed to replace growth hormone in those who have a confirmed deficiency. This deficiency may have started in childhood or developed in adulthood due to pituitary disease, surgery, radiation, or trauma. In adults, the treatment is not used for height but focuses on maintaining healthy metabolism, body fat distribution, and bone strength.

Mechanism of Action

Omnitrope contains somatropin, which is a recombinant human growth hormone. It is designed to be identical to the growth hormone naturally produced by the pituitary gland. When injected, it travels through the bloodstream and binds to specific receptors on the surface of cells throughout the body to trigger growth processes.

Growth Stimulation

The primary function of this medication is to promote linear growth, especially in children whose bodies do not produce enough natural growth hormone. It works by:

• Stimulating the growth of long bones at the growth plates.
• Increasing the production of Insulin-like Growth Factor-1 (IGF-1), a hormone that helps carry out the effects of growth hormone.
• Increasing the number and size of skeletal muscle cells.

Metabolic Effects

Beyond physical height, Omnitrope plays a role in how the body processes nutrients and maintains tissues. It influences metabolism by:

• Promoting protein synthesis to build and repair tissues.
• Encouraging the body to use stored fat for energy.
• Helping the body retain essential minerals like phosphorus, magnesium, and potassium.

Common Side Effects

Many people using Omnitrope experience mild side effects. These may include:

• Pain, redness, itching, or swelling where the medicine was injected
• Headache
• Muscle or joint pain
• Swelling in the hands, ankles, or feet (edema)
• Numbness or tingling sensations
• Cold symptoms, such as a sore throat or sneezing

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Vision changes: Sudden or severe headache, nausea, vomiting, or blurred vision.
• Stomach issues: Severe pain in the upper stomach that may spread to the back.
• Bone and joint problems: New or worsening limp, or pain in the hip or knee.
• High blood sugar: Increased thirst, frequent urination, dry mouth, or fruity breath odor.
• Ear problems: Ear pain, hearing changes, or drainage from the ear.
• Allergic reactions: Rash, hives, or swelling of the face, lips, or throat.

In children with Prader-Willi syndrome, seek emergency medical help for signs of lung or breathing problems, such as new or increased snoring or shortness of breath.

Contraindications

Omnitrope should not be used in patients with active malignancy or those with acute critical illness due to complications from major surgery, heart surgery, or respiratory failure. It is also contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy. Children with closed growth plates or those with Prader-Willi syndrome who are severely obese or have severe respiratory impairment should not use this medication.

Serious Warnings

• Increased Mortality: There is an increased risk of death in patients with acute critical illness.
• Sudden Death in Prader-Willi Syndrome: Fatalities have been reported in pediatric patients with Prader-Willi syndrome who have risk factors such as severe obesity, history of upper airway obstruction, or unidentified respiratory infection.
• Neoplasms: Patients with a history of childhood cancer may have an increased risk of developing new tumors, particularly in the brain.
• Intracranial Hypertension: This medication can cause increased pressure in the brain, leading to symptoms like headache, nausea, and visual changes.

Precautions and Monitoring

Treatment may lead to decreased insulin sensitivity, potentially causing high blood sugar or type 2 diabetes. Regular monitoring of glucose levels is recommended. Patients may also experience hypothyroidism or changes in adrenal hormone levels, which may require starting or adjusting other hormone replacement therapies.

In children, rapid growth may lead to the progression of scoliosis or a condition where the hip bone slips out of place (slipped capital femoral epiphysis). Any new limp or hip/knee pain should be evaluated. Inflammation of the pancreas (pancreatitis) has also been reported and should be considered if severe abdominal pain occurs.

Pregnancy

It is not known whether Omnitrope can cause harm to an unborn baby or affect the ability to become pregnant. Animal reproduction studies have not been performed with this medication, and human data are limited. If you are pregnant or planning to become pregnant, discuss the potential risks and benefits with your doctor. Omnitrope is generally only used during pregnancy if it is clearly needed.

Breastfeeding

There is no information available on whether Omnitrope passes into breast milk or how it might affect a nursing child. Because the risks are unknown, it is important to consult with a healthcare professional to weigh the benefits of treatment against any potential risks to the infant before breastfeeding while using this medication.

Available Forms

Omnitrope is provided as a subcutaneous injection in two primary formats:

• Cartridges: These contain a clear, colorless solution intended for use with a compatible pen injector device.
• Vials: This format consists of a lyophilized powder that must be mixed with a liquid diluent before administration.

FDA Approval History

Omnitrope (somatropin) was approved by the U.S. Food and Drug Administration (FDA) in May 2006. It was the first follow-on version of a recombinant human growth hormone to be approved under the 505(b)(2) regulatory pathway, which allows the FDA to rely on existing safety and efficacy data from a previously approved reference product.

Approved Indications

The FDA has approved Omnitrope for several specific conditions involving growth hormone deficiency or growth failure:

• Pediatric Patients: Treatment of growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, being born small for gestational age (SGA), Turner syndrome, and idiopathic short stature.
• Adult Patients: Replacement of endogenous growth hormone in adults with growth hormone deficiency that began in either childhood or adulthood.

Regulatory Status and Safety

Omnitrope is a prescription medication and is not a controlled substance, though its distribution and use are strictly regulated. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) required for this medication. However, it is contraindicated in patients with active malignancy, acute critical illness, or certain types of severe respiratory impairment. The FDA requires that the medication be used only for its approved indications under the supervision of a healthcare provider.

Factors Influencing Cost

The price of Omnitrope treatment is not fixed and varies based on several individual factors:

• Dosage and Weight: Because dosing is often based on body weight or specific medical needs, patients requiring higher doses will face higher total costs.
• Insurance Coverage: Most insurance providers require prior authorization before they will cover growth hormone therapy. The final out-of-pocket cost depends on the specific plan's deductible, copay, or coinsurance requirements.
• Pharmacy Type: Omnitrope is usually dispensed through specialty pharmacies rather than standard retail pharmacies, which can affect pricing and delivery fees.

Financial Assistance and Savings

There are options available that may help reduce the cost of Omnitrope for eligible patients:

• Co-pay Cards: The manufacturer may offer savings cards for patients with commercial insurance to help lower monthly out-of-pocket expenses.
• Patient Assistance Programs: For individuals without insurance or those who meet specific low-income criteria, programs may be available to provide the medication at a reduced cost or for free.
• Biosimilar Status: Omnitrope was the first biosimilar follow-on biologic approved in the United States, which can sometimes make it a more cost-effective option compared to other brand-name growth hormones.